Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to its letter dated September 30, 2024, Mankind Pharma has informed that the Fund Raising Committee of the Directors of the Company vide circular resolution passed today i.e. October 16, 2024, has allotted the following Non-Convertible Debentures; 1. 125,000 INR denominated, listed, rated, secured, redeemable, transferable non-convertible debentures having a face value of INR 100,000 each, aggregating up to INR 12,500,000,000 (NCD Series 1); 2. 125,000 INR denominated, listed, rated, secured, redeemable, transferable non-convertible debentures having a face value of INR 100,000 each, aggregating up to INR 12,500,000,000 (NCD Series 2); and 3. 250,000 INR denominated, listed, rated, secured, redeemable, transferable non-convertible debentures having a face value of INR 100,000 each, aggregating up to INR 25,000,000,000 (NCD Series 3). The detailed disclosures in respect of NCDs is enclosed as Annexure I.
The above information is a part of company’s filings submitted to BSE.
